Published by dtaylor at August 6, 2025 The company is optimistic about the market growth despite the price impact. Analysts expect Hypera’s entry will boost its portfolio and maintain strong market presence with strategic partnerships and regulatory submissions. Semaglutide is still under patent in the U.S., but other countries may allow generics sooner due to different patent laws and expiration dates. Alternatives to semaglutide for weight loss Firm Novo Nordisk’s global patent is set to expire in parts of the world from early 2026, allowing cut-price “generic” versions of Wegovy and Ozempic to be sold by other companies, according to reports. Along with its needed effects, a […]
